The goal of our initial work using multiple models was to demonstrate for the first time that targeting MK2 in HNSCC could reduce specific markers of regional and distant metastases compared to non-treated (or control) animals. This evidence concerns the gene MAPKAPK2 and head and neck squamous cell carcinoma.